Updates in diagnosis, management, and treatment of neuroblastoma

CC Swift, MJ Eklund, JM Kraveka, AL Alazraki - Radiographics, 2018 - pubs.rsna.org
Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the
most common extracranial solid tumor of childhood and accounts for up to 15% of all …

Peptide-based imaging agents for cancer detection

X Sun, Y Li, T Liu, Z Li, X Zhang, X Chen - Advanced drug delivery reviews, 2017 - Elsevier
Selective receptor-targeting peptide based agents have attracted considerable attention in
molecular imaging of tumor cells that overexpress corresponding peptide receptors due to …

Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors

TA Hope, EK Bergsland, MF Bozkurt… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

[HTML][HTML] Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance

DLH Chan, N Pavlakis, GP Schembri, EJ Bernard… - Theranostics, 2017 - ncbi.nlm.nih.gov
Background: PET scans using FDG and somatostatin receptor imaging agents have both
been used to study neuroendocrine tumours. Most reports have documented the sensitivity …

68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic …

SA Deppen, J Blume, AJ Bobbey, C Shah… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Neuroendocrine tumors (NETs) are uncommon tumors with increasing incidence and
prevalence. Current reports suggest that 68Ga-DOTATATE PET/CT imaging improves …

The impact of somatostatin receptor–directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis

M Barrio, J Czernin, S Fanti, V Ambrosini… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United …

E Skoura, S Michopoulou… - Journal of Nuclear …, 2016 - Soc Nuclear Med
68Ga-DOTATATE PET/CT scanning is a widely accepted method for imaging of
neuroendocrine tumors. This cross-sectional study was performed to review the first 8 y of …

Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67

CG Genc, M Falconi, S Partelli, F Muffatti… - Annals of surgical …, 2018 - Springer
Background Despite evidence of different malignant potentials, postoperative follow-up
assessment is similar for G1 and G2 pancreatic neuroendocrine tumors (panNETs) and …

Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications

R Fu, L Carroll, G Yahioglu, EO Aboagye… - …, 2018 - Wiley Online Library
Antibodies have long been recognised as potent vectors for carrying diagnostic medical
radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of …

Theranostic radiopharmaceuticals: established agents in current use

JR Ballinger - The British Journal of Radiology, 2018 - academic.oup.com
Although use of the term “theranostic” is relatively recent, the concept goes back to the
earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of …